Xtant Medical Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 05:46 pm IST
Share
Xtant Medical Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 25.02 million compared to USD 14.46 million a year ago. Net income was USD 9.23 million compared to net loss of USD 2.35 million a year ago. Basic earnings per share from continuing operations was USD 0.07 compared to basic loss per share from continuing operations of USD 0.03 a year ago. Diluted earnings per share from continuing operations was USD 0.07 compared to diluted loss per share from continuing operations of USD 0.03 a year ago.
For the nine months, sales was USD 63.2 million compared to USD 42.7 million a year ago. Net income was USD 4.96 million compared to net loss of USD 6.28 million a year ago. Basic earnings per share from continuing operations was USD 0.04 compared to basic loss per share from continuing operations of USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.04 compared to diluted loss per share from continuing operations of USD 0.07 a year ago.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.